 |
Vol.61 No.5 contents | Japanese/English |
 | Full Text of PDF (536K) Article in Japanese |
- Invited Review Article -
New Era for Treatment of Extensive-disease Small-cell Lung Cancer
Yukari Tsubata11Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, Japan
Chemotherapy is the standard treatment for extensive-disease small-cell lung cancer. However, no significant prolongation of the survival has been observed over the last 30 years, and many literature reviews have shown that new therapies are less effective in prolonging the survival than cisplatin plus etoposide or CPT-11. In 2018, the addition of atezolizumab, an anti-PD-L1 antibody, to carboplatin plus etoposide combination therapy was shown to prolong the survival and became one of the standard treatments, and durvalumab is now also used as an anti-PD-L1 inhibitor. In this article, I would like to describe the transition of treatment for extensive-disease small-cell lung cancer and highlight the latest treatment regimen, supportive care required for management and the approach to making decisions concerning treatment.
key words: Extensive-disease small-cell lung cancer, Chemotherapy combined with immune checkpoint inhibitor
JJLC 61 (5): 371-376, 2021
